Last reviewed · How we verify

Levobupivacaine lidocaine spinal anesthesia

Diskapi Teaching and Research Hospital · FDA-approved active Small molecule

Levobupivacaine and lidocaine are local anesthetics that block sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce reversible loss of sensation.

Levobupivacaine and lidocaine are local anesthetics that block sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce reversible loss of sensation. Used for Spinal anesthesia for surgical procedures.

At a glance

Generic nameLevobupivacaine lidocaine spinal anesthesia
Also known asChirocaine, Lidocaine
SponsorDiskapi Teaching and Research Hospital
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Both levobupivacaine and lidocaine are amide-type local anesthetics that inhibit voltage-gated sodium channels in the neuronal membrane, preventing depolarization and nerve impulse transmission. When administered intrathecally for spinal anesthesia, they diffuse across the dura mater to block sensory and motor nerves in the spinal cord, producing rapid onset of anesthesia in the lower body. Levobupivacaine is the S-enantiomer of bupivacaine and has a longer duration of action and potentially improved safety profile compared to lidocaine.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: